Counterscreen dataset added
Assay: SARS-CoV-2 cytopathic effect (host tox counterscreen)
Library: Anti-infective and Annotated/Bioactive Compound Collections
Screening date: 05.21.2020
Anti-infective and Annotated/Bioactive Compound Collection screening data for the SARS-CoV-2 CPE host tox counterscreen assay has been processed and uploaded – access it here. This assay serves as a counterscreen to the SARS-CoV-2 CPE assay, and measures the effect of compounds alone on Vero E6 host cell viability after 72 hours in the absence of SARS-CoV-2 virus. Compounds that directly affect Vero viability can then be excluded or deprioritized as candidates in the SARS-CoV-2 CPE assay.
Screening dataset added
Assay: SARS-CoV-2 cytopathic effect (CPE)
Library: Anti-infective and Annotated/Bioactive Compound Collections
Screening date: 05.21.2020
Anti-infective Collection screening data for the SARS-CoV-2 cytopathic effect (CPE) assay has been processed and uploaded – access it here. This assay uses live SARS-CoV-2 virus and measures the ability of compounds to reverse viral-induced CPE in Vero E6 host cells. Viral infection and replication leads to a loss of host cell viability, which is indirectly measured by an endpoint assessment of host cell viability after 72 hours. Compounds with antiviral activity protect the host cells from viral-induced CPE, thereby increasing viability.
Counterscreen dataset added
Assay: SARS-CoV-2 cytopathic effect (host tox counterscreen)
Library: Approved Drugs Collection (NPC)
Screening date: 05.13.2020
Anti-infective and Annotated/Bioactive Compound Collection screening data for the SARS-CoV-2 CPE host tox counterscreen assay has been processed and uploaded – access it here. This assay serves as a counterscreen to the SARS-CoV-2 CPE assay, and measures the effect of compounds alone on Vero E6 host cell viability after 72 hours in the absence of SARS-CoV-2 virus. Compounds that directly affect Vero viability can then be excluded or deprioritized as candidates in the SARS-CoV-2 CPE assay.
Screening dataset added
Assay: SARS-CoV-2 cytopathic effect (CPE)
Library: Approved Drugs Collection (NPC)
Screening date: 05.13.2020
Anti-infective Collection screening data for the SARS-CoV-2 cytopathic effect (CPE) assay has been processed and uploaded – access it here. This assay uses live SARS-CoV-2 virus and measures the ability of compounds to reverse viral-induced CPE in Vero E6 host cells. Viral infection and replication leads to a loss of host cell viability, which is indirectly measured by an endpoint assessment of host cell viability after 72 hours. Compounds with antiviral activity protect the host cells from viral-induced CPE, thereby increasing viability.
Screening dataset added
Assay: ACE2 enzymatic activity
Library: Anti-infective Collection
Screening date: 05.12.2020
Anti-infective Collection screening data for the ACE2 enzymatic assay has been processed and uploaded – access it here. Surface ACE2 receptor protein has been shown to be the primary host factor recognized and targeted by SARS-CoV-2 virions. This binding event between SARS-CoV-2 Spike protein and host ACE2 initiates binding of the viral capsid and eventually leads to viral entry into host cells. This ACE2 enzymatic assay serves to measure inhibition of human ACE2 to identify compounds with the potential to disrupt endogenous enzyme function.
Screening dataset added
Assay: ACE2 enzymatic activity
Library: Approved Drugs Collection (NPC)
Screening date: 05.12.2020
NPC screening data for the ACE2 enzymatic assay has been processed and uploaded – access it here. Surface ACE2 receptor protein has been shown to be the primary host factor recognized and targeted by SARS-CoV-2 virions. This binding event between SARS-CoV-2 Spike protein and host ACE2 initiates binding of the viral capsid and eventually leads to viral entry into host cells. This ACE2 enzymatic assay serves to measure inhibition of human ACE2 to identify compounds with the potential to disrupt endogenous enzyme function.
Counterscreen dataset added
Assay: Spike-ACE2 protein-protein interaction (TruHit Counterscreen)
Library: Anti-infective Collection
Screening date: 05.12.2020
Anti-infective Collection screening data for the AlphaLISA protein-protein interaction TruHit counterscreen assay has been processed and uploaded – access it here. This assay identifies agents capable of interfering with the AlphaLISA technology, and is used to flag potential artifacts from our primary Spike-ACE2 AlphaLISA assay. TruHits uses donor and acceptor beads designed to directly interact via biotin-streptavidin interactions, without the SARS-CoV-2 Spike and human ACE2 proteins.
Screening dataset added
Assay: Spike-ACE2 protein-protein interaction (AlphaLISA)
Library: Anti-infective Collection
Screening date: 05.12.2020
Anti-infective Collection screening data for the Spike-ACE2 protein-protein interaction assay has been processed and uploaded – access it here. This assay measures the ability of compounds to disrupt binding between the SARS-CoV-2 Spike protein and human ACE2 receptor. This interaction is required for SARS-CoV-2 binding to host cells, so compounds that interfere may inhibit entry of the virus.
Counterscreen dataset added
Assay: Spike-ACE2 protein-protein interaction (TruHit Counterscreen)
Library: Approved Drugs Collection (NPC)
Screening date: 05.07.2020
NPC screening data for the AlphaLISA protein-protein interaction TruHit counterscreen assay has been processed and uploaded – access it here. This assay identifies agents capable of interfering with the AlphaLISA technology, and is used to flag potential artifacts from our primary Spike-ACE2 AlphaLISA assay. TruHits uses donor and acceptor beads designed to directly interact via biotin-streptavidin interactions, without the SARS-CoV-2 Spike and human ACE2 proteins.
Screening dataset added
Assay: Spike-ACE2 protein-protein interaction (AlphaLISA)
Library: Approved Drugs Collection (NPC)
Screening date: 05.06.2020
NPC screening data for the AlphaLISA protein-protein interaction TruHit counterscreen assay has been processed and uploaded – access it here. NPC screening data for the Spike-ACE2 protein-protein interaction assay has been processed and uploaded – access it here. This assay measures the ability of compounds to disrupt binding between the SARS-CoV-2 Spike protein and human ACE2 receptor. This interaction is required for SARS-CoV-2 binding to host cells, so compounds that interfere may inhibit entry of the virus.